RANCHO CUCAMONGA, Calif. , June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar ® Pharmaceuticals, Inc. , (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Succinylcholine Chloride Injection USP,
RANCHO CUCAMONGA, Calif. , June 02, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO and Dan Dischner , Vice President of Corporate Communications and Human Resources will be presenting at the Jefferies Virtual Healthcare Conference on
Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020 RANCHO CUCAMONGA, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2020 .
RANCHO CUCAMONGA, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020 , after the market closes on Thursday, May 7th, 2020 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP
RANCHO CUCAMONGA, Calif. , April 13, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California -based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of
RANCHO CUCAMONGA , April 09, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President and Bill Peters , CFO will be presenting at the 19 th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:50 p.m.
Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31,
RANCHO CUCAMONGA, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019 , after the market closes on Thursday, March 12th, 2019 , and will hold a conference
RANCHO CUCAMONGA, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%,
